<SEC-DOCUMENT>0001178913-13-000058.txt : 20130107
<SEC-HEADER>0001178913-13-000058.hdr.sgml : 20130107
<ACCEPTANCE-DATETIME>20130107160608
ACCESSION NUMBER:		0001178913-13-000058
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130107
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130107
DATE AS OF CHANGE:		20130107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLURISTEM THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001158780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				980351734
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31392
		FILM NUMBER:		13515373

	BUSINESS ADDRESS:	
		STREET 1:		MATAM ADVANCED TECHNOLOGY PARK
		STREET 2:		BUILDING NO. 20
		CITY:			HAIFA
		STATE:			L3
		ZIP:			31905
		BUSINESS PHONE:		972-74-710-7171

	MAIL ADDRESS:	
		STREET 1:		MATAM ADVANCED TECHNOLOGY PARK
		STREET 2:		BUILDING NO. 20
		CITY:			HAIFA
		STATE:			L3
		ZIP:			31905

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLURISTEM LIFE SYSTEMS INC
		DATE OF NAME CHANGE:	20030701

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AI SOFTWARE INC
		DATE OF NAME CHANGE:	20010906
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>zk1312483.htm
<DESCRIPTION>8-K
<TEXT>
<html>
<head>
    <title>zk1312483.htm</title>
    <!--Licensed to: ZK Global-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, DC&#160;&#160;20549</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">FORM&#160;8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT PURSUANT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TO SECTION&#160;13 OR 15(d)&#160;OF THE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of report (Date of earliest event reported): <font style="DISPLAY: inline; FONT-WEIGHT: bold">January 7, 2013</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">PLURISTEM THERAPEUTICS INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact Name of Registrant as Specified in Its Charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nevada</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(State or Other Jurisdiction of Incorporation)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">001-31392</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">98-0351734</font></div>
</td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Commission File Number)</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(IRS Employer Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">MATAM Advanced Technology Park</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Building No. 20</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Haifa, Israel</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">31905</font></div>
</td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of Principal Executive Offices)</font></div>
</td>
<td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">011 972 74 710 7171</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant&#8217;s Telephone Number, Including Area Code)</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Wingdings">o</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Wingdings">o</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Wingdings">o</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 7.01.&#160;&#160;Regulation FD Disclosure.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 7, 2013, the registrant issued a letter to its shareholders as of that date. The letter is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01 Financial Statements and Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d) Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1 &#8211; Letter to the shareholders of Pluristem Therapeutics Inc. dated January 7, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="left">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PLURISTEM THERAPEUTICS INC.</font></div>
</td>
<td align="left" valign="top" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="27%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: January 7, 2013</font></div>
</td>
<td align="left" valign="top" width="4%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Yaky Yanay</font></div>
</td>
<td align="left" valign="top" width="23%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:</font></div>
</td>
<td align="left" valign="top" width="23%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Yaky Yanay</font></div>
</td>
<td align="left" valign="top" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:</font></div>
</td>
<td align="left" valign="top" width="23%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
<td align="left" valign="top" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><br>
2</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>exhibit_99-1.htm</title>
    <!--Licensed to: ZK Global Ltd-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 99.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><img src="logo.jpg" alt=""></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Pluristem's CEO Letter to Shareholders</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dear Pluristem Shareholders,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In 2012 we have made great progress and moved closer to fulfilling our vision of being a leader in developing and manufacturing cell therapies. We have had significant achievements in many areas including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Clinical trials development activity</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Exploring new potential product candidates</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Enhancing our IP position</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Insured financial soundness and joining the Tel Aviv 75 and 100 indexes</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Constructing a new state of the art manufacturing facility for our PLX Cells</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Clinical trials development activity</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Achievements in clinically developing our products attest to the hard work, dedication and ingenuity that our team demonstrates on a daily basis. In 2012 our milestones included:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The initiation of an FDA-approved Phase II clinical trial using PLX cells for the treatment of Intermittent Claudication (IC), a form of Peripheral Artery Disease (PAD)</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The approval by the Paul Erhlich Institute (PEI), the German medical regulatory body, to commence a Phase I/II clinical trial for the rehabilitation of injured gluteal muscles following a total hip replacement</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The filing with the FDA for Orphan Drug Status in using our PLX cells in the treatment of Aplastic Anemia (a disease involving bone marrow failure)</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The successful treatment of critically ill patients under a compassionate use program at the Hadassah Medical Center in Jerusalem</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The development of a Point-of-Care thawing device for our PLX Cells</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The invitation by the U.S. National Institutes of Health (NIH) to submit our PLX cells to their scientific teams to evaluate them in animal models of acute radiation syndrome (ARS)</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The formation of a Peripheral Artery Disease Steering Committee and a Hematological Diseases Clinical Advisory Board (CAB)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Exploring new potential product candidates</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have conducted several preclinical studies this year and the results of these studies demonstrate that our PLX cells may be effective in a number of indications. Because we can produce specific PLX products tailored towards the mechanism of a disease, this allows us to expand these indications. We discovered and developed a dedicated composition of PLX cells tailored to posses unique characteristics found to be beneficial in the treatment of Acute Radiation Syndrome and bone marrow illness.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In the pulmonary area, we were able to improve lung function and reduce the pulmonary fibrosis that occurs in Interstitial Lung Disease (ILD). In the cardiac area, we have demonstrated that the cardiac function in diabetic animals with heart failure was improved by using our PLX cells.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Enhancing our IP position</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">During 2012 we have invested significant efforts in strengthening our IP position. We have filed several new patent families covering new indications, new devices and manufacturing processing. We were also granted several patents and filed new applications at the National Phase stage. As of December 2012, all of this activity has led to Pluristem fully owning 22 granted patents and 95 pending applications.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Insured financial soundness and inclusion into the Tel Aviv 75 and 100 indices</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We are very proud to be included in the Tel Aviv 75 and Tel Aviv 100 indices. The TA-100 Index is one of the TASE's leading indices and is comprised of the shares of the 100 largest Israeli companies ranked by market capitalization. As a result, we now have exposure with more institutional, long-term investors who are now able to invest in our stock due to our inclusion in these indices. This is a good step in the right direction for our company as we look to bring in more institutional investors to become long-term shareholders of our stock. During 2012 we raised $34 million net in a secondary offering. With our strong cash position of approximately $65M with no debt, we are well positioned to support our research and development as well as our clinical programs with a goal of bringing PLX cells to the market for several indications.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Constructing new &#8220;state-of-the-art&#8221; manufacturing facility for our PLX Cells</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We have recently initiated the final validation steps for our new Good Manufacturing Process (GMP) facility prior to taking possession. I am extremely proud of our team in meeting milestones for the completion of this state of the art facility. We have also been hard-at-work optimizing our manufacturing process, including the scale up and automation processes, to accommodate the potential future commercial production of our PLX cells. We have initiated the &#8220;integral runs&#8221; that incorporate all the scale up and automation processes into a seamless production line. These &#8220;integral runs&#8221; will enable us to move the production line into our new manufacturing facility effectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We are very proud of the immense progress that our team has made this year. With so many major milestones on the horizon, we look forward to keeping you updated on the progress of our clinical trials, partnerships, and other activities in the coming months.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">I wish you and your families a happy, healthy and fruitful 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Thank you very much for your continued support.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Zami Aberman</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chairman and CEO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Pluristem Therapeutics</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pluristem Therapeutics Inc. (NASDAQCM:PSTI) (TASE:PLTR) is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem is focusing on the development of PLX cells administered locally to potentially treat systemic diseases and potentially obviating the need to use the intravenous route.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pluristem has a strong patent and patent applications portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit <font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">www.pluristem.com</font>, the content of which is not part of this press release.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Safe Harbor Statement</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we discuss the <font style="DISPLAY: inline; FONT-SIZE: 10pt">successful treatment of critically ill patients under a compassionate use program at </font>the Hadassah Medical Center in Jerusalem, when we discuss that our PLX cells may be effective in a number of indications based on preclinical studies that were conducted this year, when we discuss that <font style="DISPLAY: inline; FONT-SIZE: 10pt">we now have exposure with more institutional, long-term investors who are now able to invest in our stock due to our inclusion in the TA indices</font>, when we discuss that <font style="DISPLAY: inline; FONT-SIZE: 10pt">we are well positioned to support our research and development as well as our clinical programs with a goal of bringing PLX cells to the market for several indications,</font> when we discuss the <font style="DISPLAY: inline; FONT-SIZE: 10pt">potential future commercial production of our PLX cells and when we discuss the "integral runs&#8221; that will enable us to move the production line into our new manufacturing facility effectively.</font> These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contact:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pluristem Therapeutics Inc.:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">William Prather R.Ph., M.D. Sr. VP Corporate Development</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1-303-883-4954</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">William.PratherMD@pluristem.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Daya Lettvin</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Investor &amp; Media Relations Director</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">+972-54-674-5580</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">daya@pluristem.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``P("`P("
M`P,"`P,#`P,$!P4$!`0$"08'!0<*"0L+"@D*"@P-$0X,#!`,"@H.%`\0$1(3
M$Q,+#A06%!(6$1(3$O_;`$,!`P,#!`0$"`4%"!(,"@P2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$O_``!$(`(``
MZP,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/U-HHHH`****`"BBD)P>:``]>:R?$GBO2/!VEOJ/BC4+;3;-.#+
M.^-Q]%`Y8^P!->=?&G]H'3?ABCZ;I*QZIXD=,K;;OW5H".'F(.1ZA!R?8<U\
M>>*_%VL>.=8;4_%5_-?W;9"%SA(5/\,:]$7V'XY/-?#\1\;87*VZ-%<]7MT7
MJ_T7X'W7#7`V*S2*KUG[.D^O67HNWF_DF?0/CC]L3#R6_P`.=)#`<+J&I@@'
MW6$8/_?3#Z5XIXE^+OC/Q:S_`-M^)-4:)^L%M,;:+'IMCV@CZYKDMHI<5^0Y
MEQ1FN/D_:UFEV6B^Y?K<_8<LX6RG+XKV-%-]WJ_O>WRL1N@D8M(`['JS#)/X
MTH``X]*>!@T`8Z5X+DWNSWTDB(Q(3\R+^5;F@>-?$/A:4/X<US5M.P<[(+MQ
M&?K&3M/XBL@C/6DQ6E+$5J4N:G-Q?D[&56A2K1Y:D5)=FDSW?P;^UUXCTADA
M\96-KKUJ.&FA`MK@#UX^1C[87ZU]%_#[XN>&/B5`3X9U`->(NZ:PN%\JXB]<
MH?O#_:4D>]?G[CBGV]Q-974-S8S2V]S;L'AFA<H\;#H58<@_2OM<GX^S+!R4
M<0_:P\]_D_\`.Y\3G/A]EF-BY8=>RGY?#\U_E8_3(#!I:^8_@S^U*TLL&B?%
M*5%+$);ZW@(,\8%P.@_WQQZ@=:^F4<,BE6#!AD,#D$>U?LN49U@\TH>VPTK]
MUU7JC\6SC),9E5?V.)C;L^C7=/\`IH?1117K'DA1110`4444`%%%%`!1110`
M5(GW14=2)]T4`1T444`%!/%%'UH`,\\UXS^T'\<5^&^G#2/#;QR>)K^/<K$!
MA8Q'_EJP/!8\[5/U/`P>\^)?CRT^''@V^UR_`=K=-EK`3@W$[<1QCZGJ>P!/
M:OS_`-;UJ^\2ZS>:KKD[7-_J$QFGE;NQ[#T4#``[``5\#QOQ-++:"PV'?[V:
MW_E7?U?3[S]`X%X7CF==XG$*]*#V_F?;T77[BK/-+>3RSW<LD\\[EY997+O(
MQY+,3R23WIH&.M`XZTM?A+DY.[W/WI))66P4444AA1110`4444`%(1DTM(3B
M@!&48Y_+%?0O[-'QON=+U.Q\&>)WFNK"\<0Z3/M+O:OR1$<9)C/8_P`'^[]W
MYZ=U526.`!DGT%?8?[-?P73P;I$7B7Q);C^W]4B!MXY%R;"!N@'H[@@MZ#"^
MN?L^!</CZF:1EA9<JC\3Z<O9][]/OZ'Q?'>(R^EE,HXN/-*7P+KS=UV2Z^6G
M4]THHHK^@C^>`HHHH`****`"BBB@`HHHH`*D3[HJ.I$^Z*`(Z***`#-!Z&@]
M*H:YK,'A_1K[4[\XM].MI+B4_P"RBEC_`"J9SC"+E)Z(J,93DHQ5VSY&_:O\
M>'Q%XYC\/64F;#PXN)0IX>Z=06/_``%2%]B6KQ(=*T8K76O&NIWMY;6-_J=_
M<R-=78M+=YV5G8DDA02!DD5<7X?^*F.%\,>(C_W"YO\`XFOYHS:MB\TQM3%J
M$FI/2R;T6B7R1_3N4T,)E6!IX1SBG%:ZI:O5OYLPLT9K1U7PKK>A0>=K>BZO
MI\&<>;=6,D29]-S`"J5C8W.IW<5KIMO/>74Q(B@@C,CN0"3A1R>`3^!KR)X>
MM":A*+3?2SO]QZ\*]*<'.,DTNJ:L1YHJ]JGAS5M#BCDUO2M3TY)F*QM>6<D(
M<@9(!8#)Q5$<"IJ4YTY<LTT_/0JG4A4CS0::\M0HHHJ"PHHHH`,TUN36MX4\
M+:AXU\1V.BZ#&DE[?R;(][;40`$LS'LH4$GOQP":[[XG_L[Z[\,-!36;J_L=
M6T]9%CNGMHVC:V9B`I*L3N4L0,CN1Q7HX?*,;B,-/$TJ;=.&[[?UU['FXC-\
M#A\5#"U:J52>R[_\/TON)^SE\.E\??$&*748M^DZ"JWET&&5ED#?NHS]6!8^
MR$=Z^XP3WKQ_]ECPHOAWX66U])'MNO$,S7TC$<^7]R(?38H;_@1KV&OW?@O*
M8X#*J;:]^?O/Y[+Y(_!.-LVEF&;5$G[E/W5\MW\W^%@HS132W/-?6GR(ZB@=
M310`4444`%%%%`!1110`5(GW14=2)]T4`1T444`!."*\M_:6U9M)^#.O^4Q6
M2]\BT4CTDE0-_P".[J]2/6O#_P!KV8Q_"VV1?NS:Q`&]\)(?Y@5XO$=:5+*<
M3-;J$ORL>WPW15;.,-![<\?P=SSO]C-"?&'B-AD!=,C'YR__`%J[+XP_M*ZO
M\./'EWH&E:-IMY#:P0R>?<3R*Q9UW$87C`R*Y;]BZ+.N^*Y/[MG:KGZO)_A6
MAXP^#<'QD^,?C4CQ#_8]SI#V4;PFQ$_F1O;(58'S%P<AAC![5\'ELLRI\,8>
M.7NU64WV6GO-[Z=#[_,X9;/BK$SS)7I0@GLWK[B6VO4],^#/Q9B^-/AS5!JN
MEQ6L]E*+>\M2WG0S)(I((R.A&X%2.W?->&^$?"%MX-_:XM=&TH;+*TO;B6V3
M.?+C>RDD"?1=VT>P%>TZ!9>"_P!FKP7<17VK*TD[F>>25U-S?2A<!4B7V```
MX'4GJ:\+^"_B2X\=_M,P:_?1B*6_>\N/*!SY2?9V1$SWPNT9[XS77FE1R>6X
M?%R4L2IQ;M;17UO;Y>K1Q952M',\1@XN.%=.25[V;MI:_P`_1.S.T_;1N2+7
MPE;DGYI;J7\EC'_LU>#6'PQ\7ZII<6I:;X;U:YT^>+S8[J.(&-D_O`YZ<&O:
MOVTI<ZMX2B_NVUV_YM$/Z5ZAX/F_L?\`9FLKAN/)\)/-GW,#-_6O-S'):&;\
M0XR-:;2IQB]/1'J9;G=;)^',%*C!2=24EK?^9]CX>5MZAD.589!]173Z9\,/
M%^M:9#J.C^&]6O-/N$WQ7,40*.HR"0<].#7+1)LB11_"H%?<OPVF_LO]F_39
M\X\GPY--G_@#M_6OD.%LBH9M7JPK2<8PCS:6[^9]AQ7GU?**%*=**DYRY=;]
MGV/C#P[X9U?Q?=/;>%M.N]5N(HO.>*U3<RID#=CTR0/QK4M?A?XOO=>;1;?P
M[JAU6.%9I;9H@IBC;.UG8G:H)!QDC.#7IO[&$13Q[JW^QH&W_P`C1?X5ZM\<
M_CJGPGU&+3O#>FVEYKVI0K/=33DA(8QE4+`<NQPP`R``,]P#ZF6<,Y;4R>.8
MXNLX*[3M9[.R2TW9Y>:<3YE2SB66X.C&<K)J[MK:[;UM9'SKX1L_%OPJ^*VF
M16^B23^(K8EAI7F*YN(G1MRAE)`RFX@]B.AZ5Z1^T/\`%SQ'KG@R+1+SP9JW
MA>TU65?.FU-T+3M&0XCC"GIN"DD]AC`S6%\-/'%]\3/VC?#>MZU!:P79C>)U
MME8(0D$N&P22#SZ]J[C]L.4-?^`+=SE7O;AV&>P:W7_V8UZ6!I*GD.,GA*\E
M2Y[)-+5-Q6NEU=/6QYV-J>TXAP5/&4(NKR<S:;T:YGIK9I-:7N>OW7B[PQ\)
M?#6CZ?XHUBRTP6MC%!!#(^9)`B!<J@RQ''4#%95E^T9\.[V0(GB>VA8G`-Q!
M+"#^+*!7RQ\?K>_A^-.O_P#"4&X5);F-H)`NX_8R`$,8/!``88_O!N^:]ZTC
M]FKX7^+?#EO>^&IM2GM[N+,6HV^J.[$]\J<H&!ZJ5&#D8%?383/LVQ>-K87!
MTX*-%VM)M2:6EU;T^6A\KB^'\IP>"HXK&U:DI5E>\$G%-ZV=_7OKJ=]\5/B5
MIW@/PQJK-J^FV>O'3)I]+M;B5=\\@4A-J$_,-V!C\*\5^`OQXO=5\2ZU-\6/
M%EK!:+91"R2\>*VB\PNV[8`!DX`]>M=7^U#\-],U/PA<^++RYOAJ.A6$=M:Q
M(ZB)]TP&7!7)/S'H1T%>-_L]_!_2OBU<^(%\0W.H6T>DI:F$V;JI9I3+G=N4
M]HQC'O7'G68YS'B*AAZ"6S<8\S2EH]9>EG8[<DR[)9<.5\17;O=*4N5.47=:
M1\G=7]6?9VC:S8^(-/BO]#O+?4+&XR8;FWD$B2`$@X8<'D$?A7*^)?C7X(\(
MWLEGKGB.QCO(FQ);P%KB2,^C*@.T_7%>:_&W6/\`A1WPATCPIX,N[N.>_=[:
M*ZD<>=';C+RN&`&&)95!`&-V1R*\S^!G@SX;7FD3:K\5-;T@7,DS):Z7<ZD+
M?RT4X,DBA@Q+'.`>,`'G/'KX_B3%0QD,OHQ@JO*G-R=HQ\EU9X^7\,X6I@IY
MA7E-TN9J"BKSEKN^B_X?Y_3OA7XN^#_&UV+7PUK]C=7C#*VKL8I6^B.`3^&:
MZ#7=>T_PUI4^IZ_>0V%A:@&:XF;:B`D*,GZD#\:^*/CEX?\`!GA[7=+O?A'J
M]I-;W"LTT%C?^>;*9""KJVXLN<\#/!7BO9?'?B^X\9_LE-K.IG-Y>VUO'<,!
MC?(EVD;-CMDH3^-1@N*:\OK5"O&/M*,7).+O&2M_PQ>-X4H0^J5Z$I>RK246
MI*THMNWIW^[S/5],^*OA#6+"_O=,\2Z1/9Z6J->W`N0$@#9"[F/`R0<?2L:P
M_:$^'NHZ@MG;^)[)9';:CS1R0QL3T`D90OZU\L?`WX7S?%G6KS3+V^N++0;`
M1W=\(,;I9/F6)5SP&P9#N(.!G`R:G_:!^$5C\*=<TN/0[JYN=/U>WE=([HAG
MB:,J&&X`9!#@CCCGK7DRXPSEY;',8X>*I)V=V[O6VB[=+]SUX\&Y(LS>6RQ,
M_:M75DK+2^KMOUTMIYGV'XL^('A[P+;13>+=8L].6?\`U*2/EY?]Q!EF_`5F
M>$_C)X.\;7PLO#FOVD]ZX.RUD#0RR8Z[5<`M^&:^?_@U\!X_BQX=3Q'\0-5U
M1X=@L=,AAD4.((1L!+L#\H(8!0.Q))W5Y+X]\,R_#7XC:CI&FW<LLNB7L3V=
MUC8^2J2QL<=&&X`X[CMG%;8WB[-<-2I8V6'BJ$VDM?>U_!7Z:&.!X/RG%5:N
M!CB9/$4TV[+W=-/5V;2>J\C]#P>.:D3[HJ"!F:&,R_?*`MCUQS4Z?=%?HZ=U
M<_-6K,CHHHIB`]:\6_:UM#<?"-YE&?LFJ6TA/H&)3^;BO:2,BN&^-V@-XF^%
M'B>P@4O,;$SQ*HR2\1$B@?BF*\K/<.\1EF(I+=QE^1ZV0XA8?-,/5>RG&_I<
M\<_8L@&SQ?/C^*SC!Q[2G^M>4?M`7#CXU^*GB=XV6YB7<C%3Q!&.HK3^"'QS
MM_A'IFJP2Z--JCZK<QS"2.Z$0153:!RISU)_&N)^(7BI?''C;5]>BMGLTU29
M9%@=PYCPBKC<`,_=K\7Q^:827#6&PE.I^]C*[6NGQ==NI^VY?E.,AQ/BL95I
M_NIQ23TU^'I>_1]#G2-\A=OF=NK-R3^->Q?LGP>;\8(7/_+#2[E_SV+_`.S5
MX]CUKN?@Y\2HOA5XJGUFXTZ34_,L7MDB281;2S(V[)![)^M>!P_B:5#-:%:O
M*T8R3;]#W^(<-6Q&55Z-"-Y2BTEHM_P/1OVS[C/C#P[%G_5:3,X'^]+_`/8U
M[<-#N-5_9WATG15\V[NO",<-N@.-[FV&`#[GC\:^4?C3\4T^+7B.PU2#3I--
M6SL?LQBDG$NX[V;=D`?WL?A7<?"C]J.?P1X>M=#\4Z7-JMGI\8CL[FUE59DC
M'W496P&`Z`Y!P`#GK7WN`XBRM9YC)U:EJ=5)*5GVMVO^'0^`Q_#F:2R'!4Z5
M.]2BVW&ZZMOO9_?U/&-,\-:OK6L)I&E:9?3ZK(_EBT-NRNC9Q\X(^0#N3@#O
M7V_XFT8^"_V?]3TE7#MI'A>2V+KT9E@VDCZG->6>*/VRHI-.FB\&Z!=QWTB%
M8[G4I4V1$_Q;$)W8]"0*YS6?VHO[<^&UUX:O]%NYKZ\TG[%/J+WBGS)"FUI2
M@7N<G&>]3E&(R#)H8B-/%<\YQ:O9I=;+U\]BLXPW$.=3PTZN%Y(0DFUS)OI=
MO;2VRWW+7[&5MN\6^))QTBTR*/\`[ZDS_P"RUR'[4$IF^->L*Y)$-K:1CV'D
MAOYL:K?!'XQ0?"&YUB:?29=4;5(X47R[@1>6$+DYR#G.X?E7._%#QLGQ%\<Z
MCX@ALWL%OUB`MWD$A39$J?>`&<[<].]>!B\SPDN%Z."A/]XIW:UV][Y=CZ#"
M97C(\55L;.'[IPLGIO[O2]^CZ'6?LOP>?\9]()&?)MKJ0_A$1_[-7<_MIW#1
M:QX.\O):&VO9%^H>#'\J\E^$/Q"A^%_C/^WKG3Y-2VV,MLD"3"(AG9#NR0>@
M4C'O6I\;OB]%\7M1T>Z@TN72_P"RX)HF62X$OF;V0@@@#&-GZUIA,UP=+A>K
MA'/][*2=M=KQ\K=",5E6-J\5T<9[/]U&#7-=;VETO?KV/K/QO\._#_QI\*VC
M:K&-\L"S6&I6P'FVY=<_*W=3D94\''J`1\I^$/%NL_`#XHW>E)>K>V%OJ*VN
MJ6\3$PW*$@>8JY^60!L^N05.15_X6_!'Q)XW\)#5_`WBFWTZ*2>2"ZL_M$\!
MCD4\AO+R#E2K=!PU>E?#G]DE=$URTU3QSJMOJ7V.99H["TB81R2*<@R.W+`,
M`<`#)')(R#]+7AF6<5L-C,+A?93T;J<RLX_+?\^A\QAYY9DM#$X/%XOVM/5*
MGRNZEY7V^3MU.U_:DG\GX,ZL`?\`6W5JG_D93_2O//V*WC#>,D#+YS&Q;9GD
MJ/.YQZ9)KW;XC^![;XC>#]0T'49I+=;Q5,<\:Y,,BL&1L=P"!D=QD5\VK^QW
MXK@O?]%\1:)'%RHG3ST?:>OR@?INKV,[P>94L^H9AAZ'M8QC:R:6KNNOJ>-D
M.-RRKP_7RW$U_92E).[3>BY7T]#?_;0TR9[;PKJ:`M:Q2W%J[#HLCA67/U$;
M_E5G]G#P=\/_`!YX!BCU?P_HFH^(-,EDCU`W%NKS,&D9HG.>2I0@`_[)':O7
M;;X7Z3/\,+'P5KT2WMA:Z?%;2.H,99T`_>J<Y5MP+`_SKPK4OV/M;TS4OM/@
MKQ5;IL8^1)<K);SQ@]M\><GW`'TK''Y3CJ&;_P!I4\.JT9Q2E"ZO%V6U].GY
MFV79O@<1D_\`9E3$NC*G)N,TG:2N][:]7IZ;GMDOP0^'5M$TL_@_PW%&@RSR
M6:!0/4D\"N/_`&D=+L/"OP%N=,T&SMM/L$O+2."VMHPD:`SJYP!P,G)_&N+L
MOV5O%>K:E9S>.O%]O?6UM<1RO"\D]WO56!*CS"`,@$9YQFO9?C-\.;CXI^#A
MH=CJ$.FM]MBN&FEA,H(3=\N`1SDCOVKTY4L1B\NQ,8X-4I.+45[MY77EM\V>
M7&MA\)F6%E/'.M",E*3M*T;-=[W>^R/*?V+[8?V/XLN`/F:\MXL^RQLW_L]8
M?[:$^[Q)X2A_YYV%TY'^])$/_9:]B^!WPDN/A%HVJV5YJ4&J/J5Z+@216YB"
M`1JFT@L<\J3^-8GQM^`M[\6]?T[4;36[738["S-OY4MHTI8ERQ;(88Z@?A7F
MXC),<^$XX&%/][I=77\UWK>VQZ>'SS`+BZ6/G4_=:VE9_P`EEI:^_D='^S[;
MB#X,>%`H`WV1D/U9V8_SKY2^,[?VA\?=?3J)-:M8<?1(4_I7V?\`#[PP_@KP
M1HF@S7"7;Z39I;O.B%%D*CE@"3C/UKQKQ!^R]J&N_$:Y\3MXCLHXKC6$OS;&
MQ<L%616";M^,X7&<5MQ%DV,Q658/#4:=W!QYE=:)1L]V9<-YU@<+F^,Q5>I:
M,U/E=GJW*ZV7;N?1!&"<>M/3[HJ/.>?6I$^Z*^^/STCHHHH`*1E5E(=0RD8(
M(X(]*6@C(HW`_.GXA^$'\!^-]9T%U*QV%R1;$_Q0-\T1'_`&4?4&N?`R.:^J
M?VN?ARVHZ7:>,=*BW3:6HMM2"CDVY)*2'_<8D'V?/:OE4'`K^:N*,IEEF95*
M-O=;O'T?^6Q_37"^<1S3+*=:_O)6E_B6_P!^_P`QV*,4@.>M+7SY]"&*,<T4
M4`&*,8HHH`,48HHH`,4AXZ4M(1FD![G^R;X_7P]XPN?#FHR^79^(E#6Q8\+=
MH.![;TR/JBCO7J^N^(?'.@S>-=_BG39T\(:-%J`SH2I]H:2.=@A_>':!Y2\C
M.<FOC>&:6TGBFM)'AGAD62*5#AHW4Y5@>Q!`-?77POO;+XX>$O&$UUJ36NM^
M(-.MM-UBW2)3]E\M)$69!GYED#LPSC!!':OU;@O-YXG#++W)J<+N.MKJSTW5
M[2L_3R3/RCC;)X8;$O,E%.$^52O%.S4EKL[7C=>J[M'5S?&R'0+%I?'6A:KH
M;_V8+ZV,TD#_`&Q0\<94;)"(WWS1\.0`&R2`&Q3TS]H*SUVZAT_0-#N]4UF6
MX\D65EJ5I,H!B:4/YZR&/;A'!&<@C&.1GH_&?PRMO&=];75S?W-F]EIYMK4P
M1J6AE$\,Z3#=D$J]NHVD$$$@T6'@&_.MZ3JNOZW'>W&DO<&*.UTQ+1&$L0CQ
M@,QR,%LDGDXX%?H+CFBJJ*E[NFMHW:ZWUT?;1GYS&>52I.4H^_KI>5D[:='=
M/KJO+0R=6^.%IX=U2XLO$NBWVGO%:W5S$@OK6>618(VD;,22%HPRHVTM@9P#
M@G%2:G\:K;PQ;W#^.-#U/0)1:"ZLHI9X)A>J9$C*JZ.55@\L0(<J`'W9P&(Y
M+Q+\"+W3/!5[;Z1?KJ;6%A>1V-I;:5'!<7<L\+0F2>8-^\EVN<L0,G)(KK+[
MX03^(%6;Q9XDN]0U"RMXXM*NHK*.'["4ECE\PI\RR2,\,6XG"D+@*N36$:N;
MMRBHV=M+\MOFUOY6MYG0Z63I0DY7CL[<U].R>VCUO?KRZC_!GQLTOQIK%OI5
MC:NE]+-)'*(KV"ZCB58O,#^9$[*P."N`<@@Y`&":'B'XQWEMK5_IVCZ)</!8
MVFIM<7YEB)B:T,0:18V<;D7S02#@G(`_BQLR^`-<FDLKYO$UO'K6G3RFVN(M
M%1(!%(BJ\;0[\MDJ&W;P0>.F0<-O@;=+;S"/Q7=/=7T&IP:A<S:?&[3QWKH[
M[0&`1E*``C(QQ@=:TF\U<%%)WO>_NK333=ZWO?RV[$4UE*FY75K6M[[UUUV6
MFUO/?N:>E_%6>ZL9+BVT#5]5L-*B":KJL`AB59TA#RA("^]]I."$!^8D#=@U
MHV/CNYUKX>:IXC@TU],$6G375B9;F&Y29!"720&)F&,\$$@Y!^M5M/\`AWJ_
MA][N'PIXIDT[3[R=KIK>73([AHIV4;C&Y881F&\J03DL`P!&)-%^&?\`97@_
MQ'HDFI;I/$K7+S2V]FL$-J\\>QC#`"0HSER-QW.S'O6]+^T-II[._P`-K]+.
M]_OMYG/4_L_XHM;K^:]NMU:U_2ZZ)=3$TWXRW:Z//<WOAO5KVWT."W&MZI;R
M01Q1NUO%-(T<;.'8*)02J@X'3)XKIM$\=S>(]7:+1]`U*?14NIK4ZTTT*1&2
M(LKE8R_F%!(C)NV\D9`*\U5'PQC7PCXDT*/4YE7Q',TC7`@&8`88HMH7//RP
MCKZ^U)I_@'6=!CN[/PUXH:QTF:6XGMK:32XYY+629F<XD+#<@D=F"E<]MV!1
M268PE'VEVNMN6][O37I:U^MPK/+IQE[.R?GS6M9:Z7UO>W2WROW8Z5(GW144
M8*HH8[B!R<8S4J?=%>V>(1T444`%!&1110!!>V,.HV<]K?Q1SVUU$T4T4BY6
M1&&&4CT()%?!OQG^%-U\*O%;VJK)+HM\S2:7=,,Y3/,3'^^F0#ZC#=SC[YK`
M\<>!]*^(/AVYT;Q'!YMM/\R2+@202#[LB-V8?RR#D$BOE^*>'*><83E6E2.L
M7^C\F?4\*<25,FQ?,]:<M)+]5YK\=C\Z%Z<4M=?\3OA;K/PJUO['KB>=97#'
M[#J,:XCNE';_`&7`ZJ?J,CFN/W<5_/6+PE?"5I4:T7&2W3/Z)PF+H8NC&M0D
MI1ELU_7X"T49XHKG.D****`"BBB@`HH)I,T`#=.:ZOX4ZKXDTGQ]I3_#U6EU
MF>7RDM^L<\9^^LO_`$SP,D_PXR.0*P=$T._\3:O;:7X?M);[4+QML,$0R6]2
M3T"CN3P.]?:_P1^"5G\*M+:XO6BO?$5]&!>7:C*Q+U\J+/(7ID]6(R<``#ZW
MA+(,9F.,C5IMPA!W<EY=%Y_EU/D>+^(,'EN"E2J)3G--*+ZWZOR_/H>G1%BB
M^8%#X&X*<@''.#Z4_'-`&.@I:_HCH?SD!%)C%+10`F*,8-+10`8I,4M%`!B@
MCTHHH``,"I$^Z*CJ1/NB@".BG;#Z4;#Z4`-HIVP^E&P^E`#:*=L/I1L/I0!E
M^(O#NF^*](N-+\16<-_872[98)5R#Z$'J&'4$8(/(KY2^*'[*NK^'I)K_P"'
MIDUO3,EC8N?]+@'HO:4#\&]FZU]@[#Z4GEGL!7A9UP[@<VI\N(C[RVDMU_79
MGNY)Q'C\HJ<V'E[KWB]4_ET?FM3\R9X9;6>2"ZBE@N(6VRPRQE'C/HRGD'V-
M`Z5^AOC+X7>&O'T>/%6C6E[*!A+D+Y<Z#VE7#`>V<5XMXE_8PM)G:3P?XANK
M/NL&HP"X4>V]2I'X@FORG,O#G,J#;PS52/W/[GI^)^M9;XD99B$EB4Z<OO7W
MK7\#Y;HKV74_V2?'MBY^Q#1=14'Y3#>F,G\'48_.LEOV8_B2IQ_8$;>XU*WQ
M^KU\S4X9SFF[/"S^46_RN?3TN)LFJ*\<5#YR2_.QYA17K=E^RI\0[MP)[#3;
M,?WI]10_^@;J[30/V+[^1U?Q5XDMH$_BATZU,C?]_'(`_P"^371AN$,[KNRP
M[7K[OYG-B>,,CPZ;EB(O_#[WY7/FUF"`EB`!U).*])^&WP"\4_$:2*=+9M'T
M=SEM1OHF0.O_`$RC.#)]>%_VJ^J/!?[/7@OP1)'/9:2NH7T9R+S4F%PX/JH(
MV*?=5%>CK&0.1TK[G)_#51DJF83O_=C^K_R^\^%SGQ,<HNGE].W]Z7Z+_-_(
MXSX;?"C0/A=IAM_#MNSW4Z@7=_/\T]P1ZGLOHJX`],Y-=D!CH:=L/I1L/I7Z
MCAL-1PU)4J,5&*V2/RO$XFMB:KJUI.4GNWN)13MA]*-A]*W,!M%.V'THV'TH
L`;13MA]*-A]*`&T4[8?2C8?2@!M%.V'THV'TH`;4B?=%-V'TIZC"\T`?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
